Serum calprotectin in Behcet's disease
https://doi.org/10.14412/1996-7012-2024-6-61-66
Abstract
Objective: to assess the level of serum calprotectin (CLP) in Behcet's disease (BD).
Material and methods. The study included 90 patients with BD (35 women and 55 men) and 30 healthy controls (22 women and 8 men). The mean age of the BD patients was 32 [26; 37] years, that of the control subjects was 30 [25; 37] years. Serum CLP levels were measured with an enzyme immunoassay using a reagent kit from Bulhmann Laboratories AG (Switzerland). Results and discussion. CLP levels were statistically significantly higher in patients with BD compared to healthy controls (median 4.08 [2.81; 7.25] vs. 2.86 [2.15; 3.92] μg/ml; p=0.003). Elevated serum CLP levels were found in 23 (26%) of the 90 patients with BD. Patients with high CLP levels were more likely to have active uveitis (odds ratio, OR 4.741; p=0.011), pustulosis (OR 3.41; p=0.044), arthritis (OR 13.89; p=0.014) and high BD activity (OR 3.195; p=0.029). A direct correlation was found between CLP level and BDCAF activity index (rs=0.415, p<0.0001), CRP (rs=0.466, p <0.0001) and ESR (rs=0.357, p=0.001).
Conclusion. Serum CLP levels are elevated in patients with BD and are associated with high disease activity, active uveitis, pustulosis and arthritis.
Supporting agencies: The article was prepared within the framework of the basic scientific topic № 122040400024-7.
About the Authors
K. S. Nurbaeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
M. V. Cherkasova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
R. G. Goloeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology; Department of Rheumatology Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia
Russian Federation
Russian Federation
Tatyana Magomedalievna Reshetnyak
34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993
References
1. Lisitsyna TA, Alekberova ZS, Goloeva RG, Davydova GA. Behcet's disease: clinical manifestations, current principles of diagnosis and therapy. Nauchno-prakticheskaya revmatologiya. 2019;57(5):553-563. (In Russ.)
2. Le Joncour A, Cacoub P, Boulaftali Y, et al. Neutrophil, NETs and Behcet's disease: A review. Clin Immunol. 2023 May;250:109318. doi: 10.1016/j.clim.2023.109318.
3. Nurbaeva KS, Lisitsyna TA, Lila AM, Reshetnyak TM. The role of neutrophils in the pathogenesis of Behcet's disease. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022;16(4):74-79. (In Russ.)
4. Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic science to clinical application. Pharmacol Ther. 2016 Nov;167: 120-131. doi: 10.1016/j.pharmthera.2016.07.015.
5. Saviano A, Migneco A, Brigida M, et al. Serum Calprotectin in the Evalua-tion of Gastrointestinal Diseases: An Ace up Your Sleeve? Medicina (Kaunas). 2024 May 5; 60(5):762. doi: 10.3390/medicina60050762.
6. Kopec-Medrek M, Widuchowska M, Kucharz EJ. Calprotectin in rheumatic diseases: a review. Reumatologia. 2016;54(6): 306-309. doi: 10.5114/reum.2016.64907. Epub 2016 Dec 30.
7. Jukic A, Bakiri L, Wagner EF, et al. Calprotectin: from biomarker to biological function. Gut. 2021 Oct;70(10):1978-1988. doi: 10.1136/gutjnl-2021-324855.
8. Manfredi M, Van Hoovels L, Benucci M, et al. Circulating Calprotectin (cCLP) in autoimmune diseases. Autoimmun Rev. 2023 May;22(5):103295. doi: 10.1016/j.autrev.2023.103295.
9. Özseker B, Sahin C, Özseker HS, et al. The Role of Fecal Calprotectin in Evaluating Intestinal Involvement of Behcet's Disease. Dis Markers. 2016;2016:5423043. doi: 10.1155/2016/5423043.
10. Kim DH, Park Y, Kim B, et al. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behcet's disease. J Gastroenterol Hepatol. 2017 Mar;32(3): 595-601. doi: 10.1111/jgh.13530.
11. Hayashida M, Miyoshi J, Mitsui T, et al. Elevated fecal calprotectin and lactoferrin associated with small intestinal lesions in patients with Behcet disease. J Gastroenterol Hepatol. 2020 Aug;35(8):1340-1346. doi: 10.1111/jgh.14995.
12. Azramezani Kopi T, Shahrokh S, Mirzaei S, et al. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench. 2019 Summer;12(3):183-189.
13. Alibaz-Oner F, Direskeneli H. Update on the Diagnosis of Behcet's Disease. Diagnostics (Basel). 2022 Dec 23;13(1):41. doi: 10.3390/diagnostics13010041.
14. Cantarini L, Pucino V, Vitale A, et al. Immunometabolic biomarkers of inflammation in Behcet's disease: relationship with epidemiological profile, disease activity and therapeutic regimens. Clin Exp Immunol. 2016 May;184(2): 197-207. doi: 10.1111/cei.12768.
15. International Team for the Revision of the International Criteria for Behзet's Disease (ITR-ICBD). The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338-47. doi: 10.1111/jdv.12107.
16. Bhakta BB, Brennan P, James TE, et al. Behcet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999 Aug;38(8):728-33. doi: 10.1093/rheumatology/38.8.728.
17. Zouboulis CC, Vaiopoulos G, Marcomichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behcet's disease in Greece. Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S19-26.
18. Oktayoglu P, Mete N, Caglayan M, et al. Elevated serum levels of calprotectin (MRP8/MRP14) in patients with Behcet's disease and its association with disease activity and quality of life. Scand J Clin Lab Invest. 2015 Apr;75(2):106-12. doi: 10.3109/00365513.2014.984319.
19. Karada A. Serum Calprotectin and Iron Metabolism Biomarker Levels in Behcet’s Disease. Turkish Journal of Osteoporosis. 2021; 27(3):140–144. doi: 10.4274/tod.galenos.2021.45403.
20. Omma A, Sandikci SC, Colak S, et al. Serum calprotectin and ischemia modified albumin levels as markers of disease activity in Behcet's disease. Postepy Dermatol Alergol. 2018 Dec;35(6):609-613. doi: 10.5114/pdia.2017.71269.
21. Avdeeva AS. Clinical significance of calprotectin in rheumatic diseases. Nauchno-prakticheskaya revmatologiya. 2018;56(4):494-499. (In Russ.).
22. Inciarte-Mundo J, Frade-Sosa B, Sanmarti R. From bench to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Front Immunol. 2022 Nov 3;13: 1001025. doi: 10.3389/fimmu.2022.1001025.
23. Torgutalp M, Kelesoglu Dincer A, Yayla E, et al. Serum calprotectin levels in behзet’s disease: relationships between disease activity and clinical parameters. Ann Rheum Dis. 2018;77:504.
24. Olson JA, Forrester M, Clohessy PA, et al. Calprotectin is raised in endogenous posterior uveitis. Ocul Immunol Inflamm. 1996;4(2): 91-8. doi: 10.3109/09273949609079638.
25. Abd El Meged Nage S, Esmail A. Calprotectin as a Biomarker for Diagnosis and Severity of Acute Noninfectious Anterior Uveitis in Egyptian Patients. Clin Ophthalmol. 2022 Dec 13;16:4109-4120. doi: 10.2147/OPTH.S389780.
26. Song G, Huang J, Deng Y, et al. The Expression of Calprotectin and Factors in TLR4/NF- B/MyD88 Pathway in Patients with Idiopathic Acute Anterior Uveitis. Ocul Immunol Inflamm. 2019;27(7):1144-1148. doi: 10.1080/09273948.2018.1485956.
27. Jarlborg M, Courvoisier DS, Lamacchia C, et al. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Res Ther. 2020 May 6;22(1):105. doi: 10.1186/s13075-020-02190-3.
28. Ma Y, Fan D, Xu S, et al. Calprotectin in spondyloarthritis: A systematic review and meta-analysis. Int Immunopharmacol. 2020 Nov;88:106948. doi: 10.1016/j.intimp.2020.106948.
29. Ometto F, Friso L, Astorri D, et al. Calprotectin in rheumatic diseases. Exp Biol Med (Maywood). 2017 Apr;242(8):859-873. doi: 10.1177/1535370216681551. Epub 2016 Jan 1.
30. Hurnakova J, Hulejova H, Zavada J, et al. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. PLoS One. 2016 Nov 10;11(11):e0165498. doi: 10.1371/journal.pone.0165498.
Review
For citations:
Nurbaeva KS, Cherkasova MV, Goloeva RG, Lila AM, Reshetnyak TM. Serum calprotectin in Behcet's disease. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2024;18(6):61-66. (In Russ.) https://doi.org/10.14412/1996-7012-2024-6-61-66
Views:
806
Email this article 